<DOC>
	<DOCNO>NCT02772107</DOCNO>
	<brief_summary>Temozolomide may delay progression sequence chemotherapy . This open-label , randomize , multicenter phase II trial design evaluate role Temozolomide follow 4 6 cycle platinum-based first-line chemotherapy patient newly diagnose estensive-stage SCLC .</brief_summary>
	<brief_title>Temozolomide Maintenance Therapy Following Induction Chemotherapy Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Cytologically and/or histologically confirm smallcell lung cancer extensivestage disease Patients must measurable disease , include brain metastasis Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Adequate bone marrow function , define : absolute neutrophil count ( ANC ) &gt; 1,500/µL ; platelet &gt; 100,000/µL ; hemoglobin &gt; =9.0 g/dL Normal organ function , define follow : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; =2.5 × upper limit normal ( ULN ) , AST ALT &lt; =5 × ULN liver function abnormality due underlying malignancy ; total serum bilirubin &lt; =1.5 × ULN ; serum creatinine &lt; =1.5 × ULN time interval data last chemotherapy random must 3 7 week Women childbearing potential men partner childbearing potential must agree use form birth control acceptable physician prevent pregnancy treatment Patients must inform investigational nature study sign inform consent form Patients pregnant breastfeed Patients receive investigational agent Patients leptomeningeal involvement Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition HIVpositive patient combination antiretroviral therapy . However , HIV test require entry protocol . The need exclude patient AIDS protocol necessary patient increase risk lethal infection treat marrow suppressive therapy . Excluding patient HAART necessary due potential pharmacokinetic interaction temozolomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Small Cell Lung Carcinoma</keyword>
</DOC>